NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
JSLL to Establish New Day Care Clinic in Ayodhya with ₹50 Lakh Investment
Jeena Sikho Lifecare Limited (JSLL) has announced the establishment of a new Day Care Clinic in Ayodhya, Uttar Pradesh, specializing in Panchakarma services. The facility will cover approximately 2,300 sq. ft. and is slated to commence operations by August 2026. The total investment required for this expansion is approximately ₹50 lakhs, which the company plans to fund entirely through internal accruals. This move is part of JSLL's strategic objective to broaden its healthcare network and reach a larger population base.
முக்கிய அம்சங்கள்
New Day Care Clinic to be established in Ayodhya, UP, spanning approximately 2,300 sq. ft.Total capital expenditure for the project is estimated at ₹50 lakhs.The expansion will be funded through the company's internal finance (owned funds).Operations at the new facility are expected to commence by August 2026.The clinic aims to provide quality Panchakarma services as part of a wider healthcare network expansion.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step towards organic growth and geographic diversification. The use of internal accruals for expansion suggests a strong cash position and low debt risk.
Jeena Sikho Lifecare Commences Operations of 100-Bed Hospital in Mathura, UP
Jeena Sikho Lifecare Limited (JSLL) has officially commenced operations at its new hospital facility, Sanskriti Ayurvedic P.G. Medical College & Hospital, in Mathura, Uttar Pradesh. The facility is spread across approximately 60,000 sq. ft. and features a 100-bed capacity along with 8 OPD units. This expansion is a key part of the company's strategy to strengthen its Ayurvedic healthcare infrastructure and accessibility in India. The commencement of this facility is expected to contribute to the company's revenue growth and operational presence in the North Indian region.
முக்கிய அம்சங்கள்
Commencement of a new 100-bed hospital facility in Mathura, Uttar Pradesh, effective June 10, 2026.The facility spans a significant area of approximately 60,000 sq. ft.Equipped with 8 OPD units to provide integrated and holistic Ayurvedic healthcare services.Strategic expansion aimed at strengthening the company's healthcare infrastructure and market presence.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth milestone and monitor the facility's occupancy rates and contribution to the company's future earnings. The expansion validates the company's commitment to scaling its Ayurvedic healthcare model.
Jeena Sikho Lifecare FY26 PAT Surges 177% to ₹222 Cr; EBITDA Margin Hits 44%
Jeena Sikho Lifecare (JSLL) reported a stellar FY26 with revenue rising 71% to ₹801 crores and PAT jumping 177% to ₹222 crores. The company achieved a significant EBITDA margin of 44%, supported by a 65% increase in IPD patient volumes and strong sales from its Ayurveda product vertical. JSLL remains debt-free and is scaling its infrastructure, targeting up to 10,000 beds in the next 3-5 years. While Q4 saw some one-time accounting provisions, the core business model remains highly capital-efficient with a 71% ROCE.
முக்கிய அம்சங்கள்
FY26 Revenue grew 71% YoY to ₹801 crores; PAT increased 177% to ₹222 crores.EBITDA margins expanded by 1,360 basis points to reach 44% for the full year.Ayurveda products contributed 52% of total revenue (₹416 crores) with gross margins exceeding 85%.Operational beds to increase from 2,300 to 3,000 within 4 months, targeting 10,000 in 5 years.Zero debt on the balance sheet with a robust 3-year average ROCE of 71%.
👀 கவனிக்க வேண்டியவை
The company's high capital efficiency and aggressive expansion into the mainstream healthcare space make it a strong growth play. Investors should monitor the execution of the bed capacity ramp-up and the performance of the new OTC retail segment.
Jeena Sikho Lifecare Q4FY26 PAT Jumps 79% YoY to ₹45.35 Cr; Proposes ₹4.50 Dividend
Jeena Sikho Lifecare Limited (JSLL) reported a robust 55% YoY growth in revenue for Q4 FY26, reaching ₹215.55 crore. Profitability surged significantly with PAT increasing 79% YoY to ₹45.35 crore, driven by strong patient volumes in both IPD and OPD segments. The company has expanded its operational bed capacity to 2,300 and recommended a final dividend of ₹4.50 per share. While YoY performance is strong, EBITDA margins saw a sequential dip to 36% from 45% in Q3 due to one-time provisions for labor codes and ESOPs.
முக்கிய அம்சங்கள்
Revenue from operations grew 55% YoY to ₹215.55 crore in Q4 FY26.Profit After Tax (PAT) surged 79% YoY to ₹45.35 crore with a PAT margin of 21%.Board recommended a final dividend of ₹4.50 per equity share of face value ₹2.Total operational beds reached 2,300 with an additional 561 beds recently added to the network.IPD patient volumes increased by 70% YoY to 10,911, while OPD volumes grew 56% YoY to 1.50 lakh.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's aggressive capacity expansion and its ability to maintain high margins despite sequential fluctuations. The strong dividend payout and YoY growth trajectory suggest a healthy outlook for the holistic healthcare sector.
JSLL Recommends Rs 4.50 Dividend and Reports FY26 Audited Results with Unmodified Opinion
Jeena Sikho Lifecare Limited (JSLL) has approved its audited financial results for the fiscal year ended March 31, 2026, with the statutory auditors issuing an unmodified opinion. The Board has recommended a final dividend of Rs 4.50 per equity share (225% of face value), pending shareholder approval at the AGM. The audit for FY26 was conducted by Walker Chandiok & Co LLP, marking a transition from the previous auditor KRA & Co. Additionally, the company has re-appointed Forvis Mazars LLP as internal auditors for FY 2026-27.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 4.50 per equity share on a face value of Rs 2 for FY 2025-26.Statutory Auditors Walker Chandiok & Co LLP issued a clean, unmodified audit report for both standalone and consolidated results.Re-appointed M/s Forvis Mazars LLP as the Internal Auditor for the Financial Year 2026-27.The audit transition from KRA & Co. to Walker Chandiok & Co LLP was completed successfully for the FY26 reporting cycle.
👀 கவனிக்க வேண்டியவை
Investors should view the substantial dividend recommendation and the engagement of a top-tier audit firm as signs of financial health and improved corporate governance. Monitor the upcoming AGM for the final dividend declaration date.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Jeena Sikho Lifecare to Sell Non-Operational Land in Punjab for ₹24 Crore
Jeena Sikho Lifecare Limited (JSLL) has approved the sale of a non-operational land parcel admeasuring approximately 48 Bigha in Patiala, Punjab. The land is being sold to Tresco Realty Group LLP for a total consideration of ₹24 crore. As the asset is currently idle, the company confirms that the sale will have no impact on its existing business operations. This move is aimed at monetizing non-core assets to potentially strengthen the company's balance sheet.
முக்கிய அம்சங்கள்
Sale of 48 Bigha land parcel located on the Chandigarh–Bathinda Highway in PunjabAggregate sale consideration fixed at ₹24,00,00,000 (₹24 Crores)The transaction is with Tresco Realty Group LLP, a non-related partyNo impact on business operations as the land was non-operationalCompletion is subject to fulfillment of conditions including the partition (taksim) of the property
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive value-unlocking event that improves the company's liquidity without affecting core operations. Monitor the company's future announcements regarding the utilization of these funds for growth or debt reduction.
JSLL to Sell Non-Operational Land in Punjab for ₹24 Crore
Jeena Sikho Lifecare Limited (JSLL) has approved the sale of a non-operational land parcel admeasuring approximately 48 Bigha in Patiala, Punjab. The transaction is valued at ₹24 crore and will be sold to Tresco Realty Group LLP. As the land was not being used for any business activities, the sale will have no impact on the company's current operations. This move is aimed at monetizing idle assets and improving the company's liquidity position.
முக்கிய அம்சங்கள்
Sale of 48 Bigha land located on the Chandigarh–Bathinda Highway in PunjabAggregate consideration for the sale is fixed at ₹24,00,00,000 (₹24 Crores)The buyer, Tresco Realty Group LLP, is not a related party to the company or its promotersNo impact on business operations as the asset was non-operationalTransaction involves an Agreement to Sell executed on May 7, 2026, with board approval on May 8, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move to unlock value from idle assets. Watch for future disclosures on how the company plans to utilize the ₹24 crore cash inflow, such as for debt reduction or business expansion.
JSLL Noida Hospital Receives NABH Accreditation for Panchakarma Services
Jeena Sikho Lifecare Limited (JSLL) has been awarded the prestigious NABH accreditation for its Noida hospital facility located in Sector 117. This certification specifically covers Panchakarma services and is valid through March 09, 2029. The accreditation signifies the company's adherence to national standards for patient safety and quality healthcare delivery. While this is part of the ordinary course of business, it enhances the company's brand credibility and operational excellence in the Ayurvedic healthcare sector.
முக்கிய அம்சங்கள்
NABH Certificate of Accreditation received for the Noida Hospital facility in Uttar Pradesh.The accreditation specifically covers Panchakarma services under Certification No. AH-2026-0451.The certification is valid for a period of approximately 3 years, expiring on March 09, 2029.Signifies adherence to nationally recognized standards for quality healthcare and patient safety.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that strengthens the company's brand and may lead to better insurance tie-ups. No immediate action is required, but it confirms the company's commitment to institutional quality standards.
JSLL Signs Strategic MOU with Sat Kartar Life for Patient Acquisition and Hospital Management
Jeena Sikho Lifecare Limited (JSLL) has entered into a 3-year strategic MOU with Sat Kartar Life Limited (SKL) to integrate data-driven patient acquisition with clinical infrastructure. Under the agreement, JSLL will pay a 15% revenue share on net billing for both OPD and IPD cases referred by SKL, applicable only upon actual payment receipt. The collaboration also explores a model where JSLL provides management services for new Ayurveda hospitals built by SKL, specifically targeting expansion into South India. This performance-linked partnership aims to scale JSLL's patient funnel while maintaining clinical integrity.
முக்கிய அம்சங்கள்
15% revenue share payable to SKL on net billing for both OPD and IPD cases.Performance-based payment model: JSLL pays only for converted, paying patients, not for leads or appointments.Strategic expansion into South India via operational management of SKL-owned healthcare facilities.3-year agreement term focusing on AI-driven patient acquisition and nationwide customer support.JSLL retains exclusive control over clinical operations, medical protocols, and patient data.
👀 கவனிக்க வேண்டியவை
Investors should view this as a low-risk growth strategy due to the performance-linked revenue sharing model. Monitor the execution of the South India expansion and the impact on patient volume in upcoming quarters.
JSLL Dehradun Hospital Receives NABH Accreditation Valid Until January 2029
Jeena Sikho Lifecare Limited (JSLL) has successfully secured the National Accreditation Board for Hospitals & Healthcare Providers (NABH) certification for its Dehradun facility. This accreditation specifically covers Panchakarma services at the Jakhan, Dehradun location and is valid until January 05, 2029. While this does not represent a physical expansion or capacity increase, it validates the company's adherence to high-quality healthcare standards and patient safety. Such certifications are crucial for building brand trust and potentially qualifying for government and insurance empanelments in the future.
முக்கிய அம்சங்கள்
Awarded NABH accreditation for Dehradun Hospital (Jakhan) specifically for Panchakarma services.The certification (No. AH-2026-0429) is valid for approximately three years until January 05, 2029.Signifies adherence to nationally recognized standards for quality healthcare delivery and patient safety.The accreditation occurred in the ordinary course of business and does not involve immediate capacity enhancement.
👀 கவனிக்க வேண்டியவை
This is a positive development for long-term brand equity and service quality assurance. Investors should monitor if this accreditation leads to higher patient footfall or new insurance tie-ups for the Dehradun facility.
JSLL to Establish 150-Bed Hospital in Ahmedabad with ₹1.5 Cr Investment
Jeena Sikho Lifecare Limited (JSLL) has announced the establishment of a new 150-bed hospital unit in Sanand, Ahmedabad, Gujarat. The facility will span a significant area of 1,60,000 Sq. Ft. with an estimated investment of ₹1.5 Crore. The project is expected to become operational within the next 6 months, aligning with the company's strategy to strengthen its healthcare footprint in Western India. This expansion is likely to enhance the company's service delivery capacity and revenue potential in the region.
முக்கிய அம்சங்கள்
New hospital unit to be established in Sanand, Ahmedabad with a 150-bed capacityTotal estimated area of the facility is 1,60,000 Sq. Ft.Projected investment for the establishment is ₹1.5 CroreEstimated timeline for commencement of operations is within 6 months
👀 கவனிக்க வேண்டியவை
Investors should monitor the timely commencement of the facility and its impact on the company's asset turnover and margins. The low capital expenditure relative to the bed capacity suggests an asset-light or efficient scaling model that warrants further observation.
Jeena Sikho Lifecare Q3 FY26 Revenue Surges 92% to ₹221.7 Cr; PAT Jumps 405% YoY
Jeena Sikho Lifecare reported a stellar Q3 FY26 with operational income reaching ₹221.7 crores, driven by a 247% growth in OPD and video consultations. The company achieved a record EBITDA of ₹100.8 crores with margins exceeding 45%, while PAT surged 405% YoY to ₹66.7 crores. Management highlighted a capital-light expansion strategy with a low capex of ₹3-4 lakhs per bed and plans to launch 16 new products by the end of 2026. Bed capacity has reached 2,850, with a focus on increasing occupancy which currently stands at 58%.
முக்கிய அம்சங்கள்
Revenue from operations grew 92% YoY to ₹221.7 crores, with EBITDA crossing the ₹100 crore mark for the first time.Net profit (PAT) increased by 405% YoY to ₹66.7 crores, maintaining a healthy 30% margin.Operational bed capacity reached 2,290 with a 58% occupancy rate, while total beds under development stand at 2,850.Patient volume for OPD and video consultations grew by 247% to 4.34 lakhs during the quarter.Company plans to launch 16 new products by December 2026 and has initiated international expansion in the UAE.
👀 கவனிக்க வேண்டியவை
Investors should note the strong operating leverage and high EBITDA margins as a sign of a robust business model. Monitor the successful rollout of the planned 16 products and the international expansion in the UAE for long-term growth sustainability.
Jeena Sikho Lifecare Limited (JSLL) has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting was held on February 7, 2026, and concluded with the submission of the limited review report by statutory auditors. This announcement confirms the company's adherence to SEBI Listing Regulations 30 and 33. Investors should now focus on the detailed financial tables to assess the company's performance in the wellness and lifecare sector.
முக்கிய அம்சங்கள்
Board approved unaudited standalone and consolidated results for the quarter ended December 31, 2025.Statutory Auditors issued a Limited Review Report for the nine-month period ending December 2025.The board meeting was conducted efficiently, starting at 04:05 P.M. and concluding at 04:35 P.M.Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should analyze the detailed financial statements for revenue growth and EBITDA margins once the full report is accessed. Monitor the stock for any price volatility following the earnings release.
JSLL Q3 FY26 Results: Revenue Up 92% YoY, PAT Surges 405% to ₹66.73 Crore
Jeena Sikho Lifecare Limited (JSLL) delivered exceptional Q3 FY26 performance, with revenue growing 92% YoY to ₹221.66 crore. Profitability saw a massive boost as PAT surged 405% YoY to ₹66.73 crore, supported by EBITDA margins expanding from 26% to 45%. The growth was driven by a 247% YoY increase in OPD patient volumes and an 84% rise in IPD volumes. The company is aggressively expanding with 475+ beds in the pipeline, bringing total capacity towards 2,800 beds.
முக்கிய அம்சங்கள்
Revenue from operations increased 92% YoY to ₹221.66 crore in Q3 FY26.PAT skyrocketed 405% YoY to ₹66.73 crore with PAT margins reaching 30%.EBITDA margins expanded significantly to 45% compared to 26% in Q3 FY25.OPD, COD, and Video-Call patient volumes grew 247% YoY to 4.34 lakhs.Current operational capacity is 2,290 beds with 475+ additional beds under development.
👀 கவனிக்க வேண்டியவை
Investors should view the massive margin expansion and volume growth as a sign of high operational leverage and scalability. The company's transition to the mainboard and its aggressive bed expansion pipeline make it a strong growth candidate in the Ayurvedic healthcare sector.
Jeena Sikho Lifecare Limited (JSLL) has announced its financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved both standalone and consolidated unaudited results during their meeting on February 7, 2026. The filing includes the Limited Review Report from statutory auditors, ensuring regulatory compliance under SEBI guidelines. Investors should now focus on the detailed financial statements to evaluate the company's growth and margin performance in the healthcare sector.
முக்கிய அம்சங்கள்
Board approved unaudited standalone and consolidated financial results for the quarter ended Dec 31, 2025.Statutory auditors provided a Limited Review Report for the nine-month period ending December 2025.The board meeting was conducted and concluded within a 30-minute window (04:05 P.M. to 04:35 P.M.).Compliance maintained as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should scrutinize the detailed profit and loss statements and balance sheet figures to assess the company's operational efficiency. Compare the Q3 results with previous quarters to identify any seasonal trends or growth momentum in the lifecare business.
Jeena Sikho Lifecare Commences Operations at Two New Hospitals in Siliguri and Bhagalpur
Jeena Sikho Lifecare Limited (JSLL) has officially commenced operations at two new hospital facilities in Siliguri, West Bengal, and Bhagalpur, Bihar, effective February 3, 2026. The Siliguri facility adds 35 beds and 29 rooms, while the Bhagalpur unit adds 25 beds and 18 rooms to the company's healthcare network. Both facilities occupy 10,000 sq. ft. each and include dedicated OPD services. This expansion follows through on proposals initiated in 2025, demonstrating the company's commitment to scaling its physical infrastructure in the Eastern region.
முக்கிய அம்சங்கள்
Commenced operations at two new hospitals in West Bengal and Bihar on February 3, 2026Siliguri facility features 35 beds, 29 rooms, and 3 OPDs across 10,000 sq. ft.Bhagalpur facility features 25 beds, 18 rooms, and 2 OPDs across 10,000 sq. ft.Total capacity addition of 60 beds and 47 rooms across the two new locationsExecution of expansion plans within approximately one year of initial proposal
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive operational milestone that will likely contribute to revenue growth in the coming quarters. Monitor the occupancy rates and the company's ability to scale these new centers profitably.
JSLL to Engage with 25+ Institutional Investors at Nuvama 21st India Conference
Jeena Sikho Lifecare Limited (JSLL) has scheduled a series of group meetings with over 25 prominent institutional investors and asset management companies on February 10, 2026. The meetings will take place during the Nuvama 21st India Conference at Hotel Grand Hyatt, Mumbai. Participating entities include high-profile names such as PPFAS Mutual Fund, Motilal Oswal AMC, UTI Mutual Fund, and Aditya Birla Sun Life. These interactions are intended to discuss the company's business based on publicly available information, potentially increasing institutional visibility.
முக்கிய அம்சங்கள்
Scheduled meetings with 25+ institutional investors and mutual funds on February 10, 2026.Participation from top-tier funds including PPFAS Mutual Fund, Motilal Oswal AMC, and UTI Mutual Fund.Four distinct group meeting slots scheduled between 10:00 AM and 1:50 PM.Interaction organized as part of the Nuvama 21st India Conference in Mumbai.
👀 கவனிக்க வேண்டியவை
Investors should monitor for any post-conference analyst reports or increased institutional buying activity. The high level of interest from reputed funds suggests growing institutional confidence in the company's business model.
JSLL Reports One-Year Disease-Free Cancer Care Success in Peer-Reviewed Ayush Journal
Jeena Sikho Lifecare Limited (JSLL) has published a clinical case report in the 'Ayush Journal of Integrative Oncology' documenting a successful outcome for a 53-year-old breast cancer survivor. The report highlights a one-year disease-free resolution of recurrent lymphadenopathy achieved through the company's proprietary Ayurvedic protocols and lifestyle modifications. Co-authored by the Managing Director and the R&D team, this publication provides evidence-based validation for JSLL's clinical practices. This move is intended to strengthen the company's credibility in the integrative oncology space and support its research-driven growth strategy.
முக்கிய அம்சங்கள்
Published case report in 'Ayush Journal of Integrative Oncology' documents a one-year disease-free status for a post-mastectomy patient.Clinical resolution was documented via PET-CT scans, providing objective evidence for the efficacy of the Ayurvedic interventions.The publication was co-authored by Managing Director Acharya Manish Grover and JSLL's Department of Research and Development.Treatment involved a combination of personalized Ayurvedic formulations, Panchakarma therapies, and a 'Circadian D.I.P. diet'.The report reflects the company's commitment to advancing Ayurvedic research and evidence-based clinical practices.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward clinical validation of the company's treatments, which enhances brand trust and market positioning. Monitor for further R&D milestones that could drive long-term patient acquisition and revenue growth.
JSLL Approves AED 7.53 Million Unsecured Loan to International Subsidiary
Jeena Sikho Lifecare Limited (JSLL) has approved an unsecured loan of AED 7.53 million to its wholly-owned subsidiary, Jeena Sikho International LLC. The loan, to be disbursed in two tranches, carries an interest rate of 8.5% per annum with a tenure of five years to support the subsidiary's operational requirements. Separately, the company disclosed it has paid fines imposed by the NSE and BSE for past non-compliance with SEBI Regulation 29. This capital infusion suggests a focus on international expansion while the company works to strengthen its internal compliance systems.
முக்கிய அம்சங்கள்
Approved an unsecured loan of AED 7.53 million to wholly-owned subsidiary Jeena Sikho International LLCLoan features an interest rate of 8.5% per annum on a simple interest basisThe loan tenure is set for 5 years from the date of the first disbursementPaid fines to NSE and BSE for non-compliance with Regulation 29 regarding board meeting intimationsTransaction is confirmed to be on an arm's length basis as a related party transaction
👀 கவனிக்க வேண்டியவை
Investors should monitor the growth and revenue contribution of the international subsidiary following this capital infusion. Additionally, keep a watch on the company's future regulatory filings to ensure compliance issues are fully resolved.
Jeena Sikho Lifecare to Acquire 51% Stake in UAE-based Back to Roots Ayurveda for AED 1.53 Million
Jeena Sikho Lifecare Limited (JSLL) has announced that its international subsidiary will acquire a 51% controlling stake in Abu Dhabi-based Back to Roots Ayurveda for AED 1.53 million. This acquisition marks a significant step in JSLL's global expansion strategy within the Ayurveda and wellness sector. The target entity has shown rapid growth, with turnover increasing from AED 0.77 million in 2024 to AED 2.5 million in 2025. The transaction is expected to be completed within 2-3 months via cash consideration, making it a step-down subsidiary of JSLL.
முக்கிய அம்சங்கள்
Acquisition of 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC for AED 1.53 million.Target company turnover grew over 220% year-on-year, reaching AED 2.5 million in 2025 from AED 0.77 million in 2024.The deal establishes a strategic international footprint for JSLL in the UAE's growing wellness and Panchakarma market.The acquisition is a cash-only transaction expected to be finalized within approximately 2-3 months.Back to Roots Ayurveda is a relatively new entity, incorporated in December 2023, showing high growth potential.
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this international expansion as it diversifies revenue streams into a high-margin wellness market. Monitor the successful integration of the UAE operations and its impact on consolidated profitability in the next fiscal year.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
